Log In
Print
BCIQ
Print
Print this Print this
 

Semaglutide, subcutaneous semaglutide (NN9535)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionLong-acting human glucagon-like peptide-1 (GLP-1) analog
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation

Partner

Zosano Pharma Corp.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today